
Company News
Via Nova Therapeutics Announces FDA Clearance of IND Application for VNT-101, a Novel Direct-Acting Antiviral Against Influenza A Virus
"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."